Lorazepam has been studied as preanaesthetic medication given by mouth, i.m. and i.v. Sedation and side-effects and the incidence of anterograde amnesia in patients having a standard operation under methohexitone-nitrous oxide-oxygen anaesthesia were assessed. In a preliminary study of three i.m. (2-, 4-and 8-mg) and six oral (1-, 2-, 2.5-, 4-, 5-and 8-mg) doses, the optimum dose was found to be 4 mg for patients with an average weight of 60 kg. This dose was studied in detail when given by all three routes and compared with the commercially available 2.5-.and 5-mg tablets. Even when given i.v., there was a delay of 30-40 min in the onset of maximum sedative effect and drowsiness persisted for at least 4 h. Although the onset of action by i.m. injection was slightly faster than when the drug was given by mouth this advantage was more than offset by the high frequencies of pain at the site of injection and restlessness which persisted for 20-40 min. Oral lorazepam in doses of 2.5-5.0 mg was a reliable, effective sedative which could be recommended for routine preanaesthetic medication, provided rapid recovery was not essential. Its soporific effect was accompanied by an appreciable incidence of anterograde amnesia.
The great variety of preanaesthetic medications used by anaesthetists reflects not only different pharmacological needs for certain surgical procedures, but also the difficulty of achieving reliable sedation in the vast majority of patients. The unpredictable length of many surgical procedures poses problems in timing of the administration of premedicants and often results in their optimal effects having passed off before the patient goes for operation. In modern anaesthesia, reduction of salivary secretions to uncomfortable levels before operation is rarely considered necessary. In addition, many patients prefer to be unaware of the period immediately preceding their operation. A premedicant which produces a reliable degree of anterograde amnesia would be highly desirable; this cannot be achieved reliably with any of the currently available drugs in normal doses.
Because there has been an increasing use of oral premedicants recently, present needs might be met best by a drug which can be given by i.v., i.m. or oral routes. There are few suitable available compounds to which this applies. With these points in mind, lorazepam, which is a long-acting benzodiazepine, has been evaluated in fit women under clinical conditions.
Lorazepam ( (oxazepam). It has been described by Alps, Harry and Southgate (1973) as a "broad spectrum tranquillizer". Animal studies indicate that it has 20 times the potency of chlordiazepoxide as an anti-anxiety agent (Childress and Gluckman, 1964) . Elliott and others (1971) investigated both its pharmacological actions and its side-effects in healthy adult volunteers and found no evidence of toxicity with oral doses up to 7.5 mg; 5.0 mg and 7.5 mg produced reliable sedation but this was accompanied by e.e.g. effects characteristic of hypnotics. The clinical effects of these doses lasted for up to 6-8 h and were frequently accompanied by lack of recall for events. Lorazepam has been widely used in psychiatric practice (Eaves, Jain and Swinson, 1973) and initial premedicant studies by Paymaster (1973) Turner (1973) and Wilson (1973) suggested that it would be useful in this field. Particularly notable was its good sedative effect without causing cardiovascular depression (Knapp and Fierro, 1974) . A more recent premedication study by Conner and others (1976) confirms its desirable effects and shows its superiority to pentobarbitone. Cormack, Milledge and Hanning (1976) found that normal doses were virtually free of depressant cardiovascular or respiratory side-effects. This is in agreement with the findings of Dundee, Johnston and Gray (1976) , who gave total doses of up to 488 mg i.v. to patients in an intensive care unit, that 4 mg and 8 mg i.v. had negligible effects on the cardiac output.
The effect of i.v. lorazepam on recall has been evaluated by Heisterkamp and Cohen (1975) , Dundee and George (1976) and Pandit, Heisterkamp and Cohen (1976) . These workers all comment on the reliable amnesic action of 3-5 mg which lasted up to 4 h.
The available information suggests that lorazepam is worthy of further detailed study with particular emphasis on finding the optimal premedicant dose for adults and the best route for routine administration. This is a report of a study designed to answer these questions.
METHODS

Premedication
Lorazepam was given by mouth or deep i.m. injection as routine premedication to fit women undergoing minor gynaecological operations. The patients were from two hospital units and all the operations were carried out in the morning.
The study was carried out using the method of investigating premedicant drugs described originally by Dundee, Moore and Nicholl (1962a) and subsequently evaluated by Morrison, Hill and Dundee (1968) . It has been used recently by Morrison, Clarke and Dundee (1970) to evaluate droperidol and by Dundee, Clarke and Howard (1974) in studies of metoclopramide.
Following administration of the drug the patients were left undisturbed: half of them were visited at 20, 40, 60 or 90 min and the remainder once between 60 and 90 min. At each visit several subjective and objective observations were recorded. The degree of drowsiness was graded as "good", "fair", "slight" or "nil" according to predetermined criteria. The severity of apprehension was graded as "marked", "moderate", "slight" or "absent" and the occurrence of restlessness or excitement as "marked", "slight" or "nil". Based on these three observations and the general behaviour of the patients, an efficacy score was allocated, ranging from 5 (good sedation, with no apprehension or excitement) to 1 (no sedation with marked apprehension or excitement, or both).
Where applicable, the occurrence of persistent pain at the site of injection was graded as "marked", "slight" or "nil". Emetic effects were recorded as "vomiting", "marked nausea" or "slight nausea". The decrease in the systolic arterial pressure related to the premedication was graded as "nil" (0-20 mm Hg), "moderate" (21-40 mm Hg) or "severe" (41+ mm Hg). Heart rates were classified as "no tachycardia" (less than 100 beat min-1 ), "slight tachycardia" (100-120 beat min-1 ), "moderate tachycardia" (121-140 beat min" 1 ) and "severe tachycardia" (more than 141 beat min" 1 ). On these criteria a toxic score was assigned, ranging from 5 (patients unmanageable or having severe side-effects) to 1 (no side-effects).
For each patient an "index" reading was made which assessed her state between 60 and 90 min after administration of the drug and the severity of sideeffects occurring from the time of injection to that of the final observation.
The preoperative effect of a single i.v. dose of 4 mg was studied also. This was divided into two series to determine the rate of onset and duration of action of the drug. Twenty evaluations were made at 5-min intervals for 20 min and at 10-min intervals for a further 20 min. In another 30 patients the standard evaluation was continued at half-hourly intervals for
Anaesthesia
This was standardized (Dundee, Moore and Nicholl, 1962b) ; i.v. induction was with methohexitone l^mgkg" 1 and maintenance with nitrous oxide 6 litre min" 1 and oxygen 2 litre min-1 with small supplementary doses of methohexitone as required. The observations during the course of anaesthesia included the incidence and severity of excitatory phenomena (spontaneous involuntary muscle movements, hypertonus, tremor), respiratory upset (cough, hiccup, laryngospasm), marked respiratory depression (indicating the need for assisted ventilation) and hypotensive effects attributed to the anaesthesia. Each administration was graded as 1 (smooth, uncomplicated), 2a (slight upset, not interfering with the course of anaesthesia), 2b (moderate upset which interfered with the progress of the operation) and 3 (serious difficulties which, if untreated, would make surgery impossible or place the patient's life in jeopardy).
as "awake", "safe" or "unsafe", the last indicating absence of jaw tone and protective reflexes.
Evaluation after operation
The patients were seen 1 h after the end of operation and the occurrence of vomiting or nausea was recorded. When both nausea and vomiting occurred, this was recorded as vomiting: retching also was recorded as vomiting. The same observations were made 6 h after operation and the total frequency of emetic sequelae during the first 6 h was recorded. Other sequelae after operation, such as arterial hypotension, were noted. At the 6-h visit the patients were asked for their memory of the journey to the operating theatre and of the i.v. injection of the induction agent. The memory of these events was graded as "nil", "hazy" or "clear" and, from these, the degree of amnesia was graded as "complete", "partial" or "nil".
Venous irritation
The local irritant effect of i.v. lorazepam was studied in patients who received no other drug through the same vein and in whom the 4-mg ml" 1 solution was injected without dilution. These patients were visited on the 2nd or 3rd day after operation and the results are presented according to the method described by Hewitt and others (1966) and O'Donnell, Hewitt and Dundee (1969) . This gives the incidence of phlebitis, thrombosis and thrombophlebitis.
Design of the study
Initially it was planned to carry out a pilot study of three doses, 2, 4 and 8 mg, given i.m. and orally, and to evaluate the effect of the optimal dose for each route in greater detail. The minimum number of patients in each pilot study was intended to be 20, but this had to be reduced in the case of the 8-mg dose because of the undesirable side-effects. Since lorazepam is available commercially in 1-and 2.5-mg tablets, the effects of 1, 2.5 and 5 mg were studied also, the last two in 50 patients each. The pilot study suggested that the optimal adult premedicant dose for oral and i.m. administration is 4 mg. The number of patients receiving this dose was increased to 100 for the i.m. route and 200 for the oral route.
There was no selection as to which patient received which dose of the drug and patients were not aware that they were taking part in a clinical study. The frequent visits and questioning were routine in the hospital units involved and did not seem strange to the patients. The total data presented here are based on 548 administrations of lorazepam. Table I shows the number of patients in the various series, while table II gives particulars of the patients in the series which were studied in detail, together with the average duration of methohexitone-nitrous oxide-oxygen anaesthesia. It can be seen that the series were broadly comparable with respect to average age, weight and duration of anaesthesia. 
RESULTS
Pilot study
The very long delay to full recovery following lorazepam 8 mg caused us to abandon its use, since some patients were still too drowsy for discharge on the first day after operation. Table III shows the number of patients considered to be moderately drowsy or asleep at the different times of observation. There is increasing efficacy with dosage, except for the 8-mg dose. (Persistent pain at the site of injection and restlessness in three of the 10 patients could probably account for this discrepancy.) Figure 2 shows the mean "efficacy scores" at 60 and 90 min for the six oral doses studied; this suggests that 4 mg was the optimal premedicant dose of lorazepam in these patients.
Apart from the undesirable effects of the 8-mg dose mentioned above there were no notable side-effects in the initial pilot study. Thus subsequent data are 
Main study
Compared with the oral route, the i.m. injection of lorazepam produced a slightly higher incidence of notable (good and fair) drowsiness at 40 and 60 min (table IV), the difference between them being statistically significant at both times (P<0.01). However, i.m. lorazepam was followed by a very high incidence of motor restlessness, particularly in the first 40 min after injection; the difference between the two routes with respect to this side-effect was highly significant (P< 0.0005).
Restlessness detracted from the early superior soporific effect of i.m. lorazepam (as compared with the oral administration) and this is shown by the similarity in distribution of efficacy scores with the two routes of administration. Table V shows the incidence of side-effects recorded during the first 60-90 min after administration of lorazepam 4 mg by three routes. Persistent Of the patients who received lorazepam 4 mg i.m., 40% complained of side-effects during the first 90 min after injection as compared with only 10% when the drug was given by mouth. The difference between these is highly significant (x 2 = 24.0; P< 0.0005). This can be accounted for almost entirely by the early effects of lorazepam, particularly pain and restlessness.
Onset and duration of action
One notable feature of lorazepam was the slow onset of action as compared with the commonly used premedicants. Using the mean efficacy score as a guide to the rate of onset, figure 3 shows that, even with i.v. injection, there is a delay of up to 40 min before the peak drug effect is observed. This is shown in more detail in figure 4 which is based on the degree of drowsiness. Figure 3 shows also the very long action of lorazepam which was still very effective 4£ h after i.v. injection.
Side-effects were very uncommon following the i.v. injection of lorazepam (table V).
Venous sequelae
Of the 48 patients who were studied in detail, six had localized phlebitis and there was no occurrence of thrombosis or thrombophlebitis. In addition, two further patients, in whom lorazepam was injected in a small vein on the back of the hand, complained of pain at the site of injection on the 2nd and 3rd days, but there was no local evidence of inflammation. Table VI lists the incidence of complications and the grade of anaesthesia in the patients who were premedicated with i.m. or oral lorazepam. No patients in this series had marked respiratory depression necessitating assisted ventilation and there was no incidence of a decrease in arterial systolic pressure in excess of 20 mm Hg.
Effect on course of anaesthesia
Muscle tone had not recovered in one-quarter of the patients, to the extent that they could retain their airway 2 min after the end of nitrous oxide anaesthesia (table VI). Although there was some delay in recovery as compared with patients receiving other forms of premedication, this did not cause clinical problems. Table VII gives the incidence of emetic sequelae recorded during the first 6 h after anaesthesia in the patients premedicated with oral or i.m. lorazepam. There is nothing to suggest that this premedicant has any positive emetic effect. Table VIII subject of a detailed report by Dundee and George, 1976) . The data in the total series are given since we had the clinical impression that the incidence of anterograde amnesia was dose-related; this is confirmed in table VIII. Almost half of the patients receiving the optimal dose of lorazepam 4 mg had complete amnesia for events occurring 60-90 min after the administration, irrespective of whether the drug was given by mouth or by i.m. injection. However, when one includes partial amnesia (hazy memory or memory for one event only), i.m. lorazepam caused a significantly higher frequency of amnesia (x 2 = 10.05; P< 0.025) compared with the results when the drug was given by mouth. Increasing the oral dose from 4 to 5 mg did not significantly increase the incidence of anterograde amnesia. However, with lorazepam 8 mg an absence of memory for the journey to the operating theatre and the i.v. injection of the induction agent was very common, especially when the lorazepam was given i.m.
Amnesia
DISCUSSION
It is not the purpose of this publication to compare the efficacy of lorazepam with other commonly used premedicants. This will be the subject of a further communication. The present study was designed to find the optimal dose of lorazepam for premedication in adults when it is given by mouth or by i.m. or i.v. injection.
However, it is worth comparing the effects of what proved to be the optimal dose (4 mgj_as compared with a dummy premedication using figures based on previous studies reported from this department with the same group of observers (Assaf, Dundee and Gamble, 1974; Dundee, Clarke and Howard, 1974; Assaf, Dundee and Bali, 1975; Dundee et al., 1976) . The data from the dummy preparation are based on 200 observations for each of these routes of administration. Table IX leaves little doubt that, in the doses used, lorazepam has a marked therapeutic effect as preanaesthetic medication in adults. Its soporific and anxiolytic effect is much greater than that produced by the dummy preparation and this is reflected in the overall effects as assessed by the distribution of efficacy scores. Although not shown in table IX, apart from persistent pain at the injection site in some instances and early restlessness following i.m. injection, lorazepam 4 mg produced no more sideeffects than did the dummy preparation.
One interesting action of lorazepam is the high incidence of anterograde amnesia, particularly when the drug is given by mouth. Previous studies from this department have demonstrated a transient degree of anterograde amnesia following i.v. diazepam (Dundee and Pandit, 1972) with very little amnesia when it is given by i.m. injection (Pandit and Dundee, 1970) . In unpublished studies we have been unable to demonstrate any amnesia following the oral administration of that drug. This applies, but to a lesser extent, to flunitrazepam and to other similar drugs given as premedication, and lorazepam differs in this respect. In inpatients, particularly those undergoing major surgery, this is a highly desirable effect, but in some situations it should be taken as an indication for care, particularly after minor surgery where there are few attendants to look after the patient. The medicolegal implications of amnesia must be remembered also, particularly if the patient is being told about the details of the operation or asked to sign a consent form when under the influence of the premedicant. Furthermore, if instructions are given to a patient to avoid other drugs or to take particular medicines in the period soon after operation, this could be affected by residual amnesic effect from lorazepam. Taking all factors into consideration, anterograde amnesia would appear to be a highly desirable effect of a premedicant, provided the medical and nursing staff are aware of its occurrence and implications. Another interesting aspect of lorazepam is its very long duration of action. Although the present study was, in the main, limited to 90 min, when the drug was given parenterally ( fig. 3) it can be seen that drowsiness persisted at least 4 h. When the patients were visited at the end of the working day they still showed residual drowsiness which continued for up to 6 h. This was often accompanied by a concomitant period of amnesia (Dundee and George, 1976) which may extend into the period following operation after short operative procedures. Pandit, Heisterkamp and Cohen (1976) have commented on the long period of drowsiness after lorazepam but their studies of recall throw no light on its duration. Certainly they found amnesia still present 360 min after administration of lorazepam 4 mg in an appreciable number of patients. Stoller, Bellville and Bellville (1976) , using visual tracking as a method of detecting the effect of the drug, found that both lorazepam and pentobarbitone impaired hand-eye co-ordination and their findings suggest that this effect may persist for 4h after lorazepam 2 mg and 8 h after lorazepam 4 mg. They comment that "operation of a motor vehicle or engaging in a hazardous sport or occupation should be approached with caution after using this medication".
On the basis of this study lorazepam would appear to be a very promising preanaesthetic medication. It would seem that, where feasible, the oral route should be preferred to i.m. injection. Not only pain on injection but also the early restlessness which follows its administration are avoided. Lorazepam has a slow onset of action and this must be taken into consideration when timing premedication. It would appear to be an ideal drug to use when the duration of operation in early cases on a list is uncertain, also for afternoon operating lists where patients frequently spend a very agitated morning awaiting surgery. A single tablet of lorazepam given early in the morning would obviate much of their anxiety and yet not leave them too depressed before operation.
The authors have had a limited experience in using lorazepam as a sedative on the night before operation and, in this connection, the commercially available 2.5-mg tablet has proved very satisfactory. There has been no suggestion that its effect would enhance that of normal premedication given early in the morning.
As a result of this trial we would suggest that lorazepam is a promising premedication worthy of further detailed study. To evaluate it properly, its effects will have to be compared with other forms of premedication, particularly with popular drugs such as diazepam.
RESUME
On a proc£d£ a des etudes sur le lorazepam, benzodiazepine a action prolongee, utilise en tant que medication pr6-anesthesique et administr£ par voie buccale, par injection intramusculaire et par injection intraveinuese. Ces eludes comprenaient une Evaluation de la sedation, des effets secondaires et de Pincidence de l'amnesie anterograde sur les malades ayant subi une operation chirurgicale normale sous anesth£sie provoqu£e par m6thoh6ritone-protoxyde d'azote-oxygene. Une 6tude pr61iminaire a 6t6 effecruSe avec trois doses intramusculaires de 2, 4 et 8 mg et avec six doses orales de 1, 2, 2,5, 4, 5 et 8 mg. On a trouvE que la dose optimale 6tait de 4 mg pour les malades ayant un poids moyen de 60 kg. Cette dose a 6t6 6tudi6e en plus de details lorsqu'elle a 6ti administree par chacune des trois voies puis elle a 6t£ comparee avec les comprimes de 2,5 et de 5 mg que Ton trouve dans le commerce. Meme lorsque ceux-ci ont 6t£ administres par voie intraveineuse, on a constati un delai de 30 a 40 min dans le dEclenchement de l'effet s6datif maximal et l'effet de somnolence diurne a persist^ pendant au moins 4 h. Bien que le ddclenchement de l'action par l'injection intramusculaire ait 6t£ 16gerement plus rapide que lors de radministration par voie buccale, cet avantage a ete plus que compense par la frequence elevee 
SUMARIO
Lorazepam ha sido estudiado como medicamento preanestesico suministrado oralmente, por inyecci6n intramuscular e inyeccibn intravenosa. Se esmdiaron los efectos e incidencia de amnesia anterograda en pacientes operados bajo anestesia de metohexitona-nitrosa oxido-oxigeno. En un estudio preliminar de tres dosis intramusculares (2, 4y 8 mg) y seis orales (1, 2, 2,5, 4, 5 y 8 mg) se encontro suministrada oralmente, esta ventaja fue mas que contrarque la dosis optima es de 4 mg para pacientes con un peso restada por la alta frecuencia de dolor en la zona de la promedio de 60 kg. Esta dosis fue esrudiada en detalle inyeccion y la inquietud persistente durante 20-40 min. en los tres metodos de suministro y comparado con las Lorazepam oral en dosis de 2,5-5,0 mg resulto un sedativo pastillas de 2,5 y 5 mg obtenidas comercialmente. Aun seguro y efectivo que podia ser recomendado como medicuando fuera suministrado en forma introvenosa, habia camento preanestesico rutinario, siempre que no fuera una demora de 30-40 min antes que ejerciera un maximo necesaria una recuperaci6n rapida. Su efecto soporifero efecto sedativo y la sofiolencia persistio durante por lo resulto acompaflado por una apreciable incidencia de menos 4 horas. Aunque la reaccion a la inyeccion intra-amnesia anterograda. muscular fue levemente mas rapida que cuando la droga fue
